Fluticasone furoate, umeclidinium and vilanterol dry powder triple therapy inhaler

Description

In this Product Explainer, Respiratory Physician Dr Kwok Yan explains the role of fluticasone furoate, umeclidinium and vilanterol dry powder triple therapy inhaler for the maintenance treatment of asthma in adult patients who are not adequately controlled with an ICS+LABA (7 mins).

This educational activity was developed by Healthed at the request of and with funding from GSK.

PM-AU-FVU-OGM-220003 approved June 2022

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
A/Prof Karam Kostner

A/Prof Karam Kostner

LDL Management – Why it is Important

A/Prof Ralph Audehm

A/Prof Ralph Audehm

Navigating Expanded PBS Access to SGLT2i in General Practice

Prof Deborah Bateson

Prof Deborah Bateson

Cervical Cancer Prevention – Common Questions

Clinical A/Prof Greg Katsoulotos

Clinical A/Prof Greg Katsoulotos

Asthma Cases – When to Use Dual vs Triple Therapy

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Dr Kwok Yan

expert

Dr Kwok Yan

Respiratory Physician

Date published: 14 June 2022